AU2022240650B2 - Estrogen receptor antagonist - Google Patents

Estrogen receptor antagonist Download PDF

Info

Publication number
AU2022240650B2
AU2022240650B2 AU2022240650A AU2022240650A AU2022240650B2 AU 2022240650 B2 AU2022240650 B2 AU 2022240650B2 AU 2022240650 A AU2022240650 A AU 2022240650A AU 2022240650 A AU2022240650 A AU 2022240650A AU 2022240650 B2 AU2022240650 B2 AU 2022240650B2
Authority
AU
Australia
Prior art keywords
6alkyl
halogen atom
methyl
optionally substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022240650A
Other languages
English (en)
Other versions
AU2022240650A1 (en
Inventor
Liming BAO
Chaole CHEN
Xiangyan MIN
John Jeffery TALLEY
Liangliang XU
Xuan YANG
Chaochun Zhang
Chenggang ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Forward Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Forward Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Forward Pharmaceuticals Co Ltd filed Critical Shenzhen Forward Pharmaceuticals Co Ltd
Publication of AU2022240650A1 publication Critical patent/AU2022240650A1/en
Application granted granted Critical
Publication of AU2022240650B2 publication Critical patent/AU2022240650B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2022240650A 2021-03-15 2022-03-14 Estrogen receptor antagonist Active AU2022240650B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110277849 2021-03-15
CN202110277849.3 2021-03-15
PCT/CN2022/080680 WO2022194096A1 (zh) 2021-03-15 2022-03-14 雌激素受体调节剂

Publications (2)

Publication Number Publication Date
AU2022240650A1 AU2022240650A1 (en) 2023-10-19
AU2022240650B2 true AU2022240650B2 (en) 2025-01-30

Family

ID=83246765

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022240650A Active AU2022240650B2 (en) 2021-03-15 2022-03-14 Estrogen receptor antagonist

Country Status (7)

Country Link
US (1) US20240217988A1 (https=)
EP (1) EP4310079A4 (https=)
JP (2) JP7605536B2 (https=)
KR (1) KR20230157439A (https=)
CN (2) CN115073493B (https=)
AU (1) AU2022240650B2 (https=)
WO (1) WO2022194096A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7605536B2 (ja) * 2021-03-15 2024-12-24 深▲せん▼福沃薬業有限公司 エストロゲン受容体モジュレーター

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219604A (zh) * 2016-04-08 2019-01-15 豪夫迈·罗氏有限公司 四氢异喹啉雌激素受体调节剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
WO2012142029A2 (en) * 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
CN104910137B (zh) * 2014-03-10 2017-04-19 山东轩竹医药科技有限公司 Cdk激酶抑制剂
KR20180012853A (ko) * 2015-06-16 2018-02-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도
US10125135B2 (en) * 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2018138739A1 (en) * 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
TW202003495A (zh) * 2018-05-23 2020-01-16 大陸商江蘇恒瑞醫藥股份有限公司 苯並哌啶或雜芳基並哌啶類衍生物、其製備方法及其在醫藥上的應用
JP7605536B2 (ja) * 2021-03-15 2024-12-24 深▲せん▼福沃薬業有限公司 エストロゲン受容体モジュレーター

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219604A (zh) * 2016-04-08 2019-01-15 豪夫迈·罗氏有限公司 四氢异喹啉雌激素受体调节剂及其用途

Also Published As

Publication number Publication date
EP4310079A1 (en) 2024-01-24
AU2022240650A1 (en) 2023-10-19
US20240217988A1 (en) 2024-07-04
EP4310079A4 (en) 2024-10-30
CN115073493B (zh) 2024-12-10
JP7605536B2 (ja) 2024-12-24
KR20230157439A (ko) 2023-11-16
WO2022194096A1 (zh) 2022-09-22
CN115073493A (zh) 2022-09-20
JP2024511044A (ja) 2024-03-12
JP2025023300A (ja) 2025-02-14
CN119930646A (zh) 2025-05-06

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
KR102614939B1 (ko) 피리미딘-융합고리 화합물 및 그의 제조방법과 용도
TWI841200B (zh) 雜環類化合物、藥物組成物及其應用
CN112239473B (zh) 作为hpk1抑制剂的三环化合物的制备方法
AU2019327475B2 (en) INHIBITING αV β6 INTEGRIN
AU2011323739B2 (en) CDK inhibitors
AU2009205072B2 (en) Condensed aminodihydrothiazine derivative
EP3733663A1 (en) Quinazoline derivative and use thereof
WO2022143856A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
AU2009300836A1 (en) Novel fused aminodihydrothiazine derivative
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
EP3571198A1 (en) Bicyclic amines as novel jak kinase inhibitors
CA3214088A1 (en) Pkc-theta modulators
TW202428267A (zh) 用於降解ｅｇｆｒ激酶之化合物
US20230040182A1 (en) ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
KR20250152075A (ko) 거대환식 알파4베타7 인테그린 억제제
AU2022240650B2 (en) Estrogen receptor antagonist
AU2018372752B2 (en) Pyrimidine sulfamide derivative and preparation method and medical application thereof
AU2021343770A1 (en) Amine derivative
HK40106742A (en) Estrogen receptor antagonist
WO2026039844A1 (en) Stat6 degraders and uses thereof
HK40029944A (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40029944B (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
WO2025147603A1 (en) Thienopyridine compounds and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)